Canada markets closed
  • S&P/TSX

    20,861.10
    +227.83 (+1.10%)
     
  • S&P 500

    4,591.67
    +53.24 (+1.17%)
     
  • DOW

    35,227.03
    +646.95 (+1.87%)
     
  • CAD/USD

    0.7842
    +0.0055 (+0.71%)
     
  • CRUDE OIL

    69.98
    +3.72 (+5.61%)
     
  • BTC-CAD

    62,750.81
    -0.53 (-0.00%)
     
  • CMC Crypto 200

    1,275.34
    +15.18 (+1.20%)
     
  • GOLD FUTURES

    1,777.30
    -4.70 (-0.26%)
     
  • RUSSELL 2000

    2,203.48
    +44.17 (+2.05%)
     
  • 10-Yr Bond

    1.4340
    +0.0910 (+6.78%)
     
  • NASDAQ

    15,225.15
    +139.68 (+0.93%)
     
  • VOLATILITY

    27.22
    -3.45 (-11.25%)
     
  • FTSE

    7,232.28
    +109.96 (+1.54%)
     
  • NIKKEI 225

    27,927.37
    -102.20 (-0.36%)
     
  • CAD/EUR

    0.6945
    +0.0067 (+0.97%)
     

Insider Buying: The Harpoon Therapeutics, Inc. (NASDAQ:HARP) Chief Financial Officer Just Bought 12% More Shares

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Even if it's not a huge purchase, we think it was good to see that Georgia Erbez, the Chief Financial Officer of Harpoon Therapeutics, Inc. (NASDAQ:HARP) recently shelled out US$83k to buy stock, at US$8.10 per share. That purchase might not be huge but it did increase their holding by 12%.

See our latest analysis for Harpoon Therapeutics

Harpoon Therapeutics Insider Transactions Over The Last Year

Notably, that recent purchase by Georgia Erbez is the biggest insider purchase of Harpoon Therapeutics shares that we've seen in the last year. That means that even when the share price was higher than US$7.96 (the recent price), an insider wanted to purchase shares. Their view may have changed since then, but at least it shows they felt optimistic at the time. To us, it's very important to consider the price insiders pay for shares. It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. The only individual insider to buy over the last year was Georgia Erbez.

The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
insider-trading-volume

There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

Does Harpoon Therapeutics Boast High Insider Ownership?

For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Based on our data, Harpoon Therapeutics insiders have about 1.2% of the stock, worth approximately US$3.1m. We prefer to see high levels of insider ownership.

So What Do The Harpoon Therapeutics Insider Transactions Indicate?

It's certainly positive to see the recent insider purchase. And the longer term insider transactions also give us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. While the overall levels of insider ownership are below what we'd like to see, the history of transactions imply that Harpoon Therapeutics insiders are reasonably well aligned, and optimistic for the future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Every company has risks, and we've spotted 4 warning signs for Harpoon Therapeutics (of which 1 is potentially serious!) you should know about.

But note: Harpoon Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting